Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
The Chinese HIV market has long been dominated by multinationals, but recent years saw local Chinese companies join the battlefield attracted by the huge potential - about 1.25 million infected people, according to the World Health Organization (WHO) and China’s Center for Disease Control and Prevention (CDC). 30 June 2020
Pharmaceutical
Russia may start exports of Avifavir (favipiravir), which is a newly developed domestic drug, that could be recommended for the treatment of COVID-19, according to recent statements by Sergey Tsyb, deputy head of the Russian Ministry of Industry and Trade, reports The Pharma Letter’s local correspondent. 30 June 2020
Generics
A recent Intellectual Property Appellate Board (IPAB) order has resulted in the generic version of anti-cancer drug Ibrutinib becoming illegal once again, leaving patients with no option but to go back to buying Ibrutinib, sold under the brand name Imbruvica at $5,283. The revoked patent has granted a fresh lease of life to the on-going litigation between Big pharma and domestic drug companies, reports The Pharma Letter’s India correspondent. 25 June 2020
Pharmaceutical
The COVID-19 pandemic in Russia has resulted in an increase of drug sales in the local market and led to liberalization of the domestic legislation for pharma products, according to recent statements by some leading Russian drugmakers and local analysts, reports The Pharma Letter’s correspondent. 23 June 2020
Generics
Even as China settles down post COVID-19, the Indian pharmaceutical industry is bracing itself for a reduction in profit margins in the short term, given the expected rise in the prices of active pharmaceutical ingredients (API) and key starting materials (KSM). Aiming to reduce import dependency and to attain self-reliance and drug security, the Indian government has decided to provide incentives to the pharmaceutical industry, reports The Pharma Letter’s India correspondent. 17 June 2020
Biosimilars
A Special Report from Tokyo-based Patrick Branch from LEK Consulting on the macro trends pointing towards rapid growth in Japan’s biosimilars market. 17 June 2020
Generics
The Russian Parliament (State Duma) has proposed zeroing of customs duties on the imports of active pharmaceutical ingredients (APIs), in a move to ensure stabilization of prices for some most demanded drugs available in the domestic market, according to recent statements, made by representatives of the Duma and local pharma analysts, reports The Pharma Letter’s local correspondent. 16 June 2020
Pharmaceutical
Amid the unfamiliar circumstances of the last few months, much has been made of the rapid innovation that businesses up and down the UK have been forced to undertake, writes Jameel Zayed, from innovation funding consultancy Leyton, in an Expert View piece. 15 June 2020
Biosimilars
In February 2020, the US Food and Drug Administration announced its plans to enhance the “Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations,” a database of all FDA-licensed biological products. The database is colloquially referred to as the “Purple Book.” The agency seeks to improve the accessibility of information related to biological products, including interchangeable products and biosimilars, through expansion and digitization of the Purple Book, notes Dr Nicola Davies in her exclusive article for The Pharma Letter. 12 June 2020
Biotechnology
The recognition of the existence of certain orphan or rare diseases has been a step forward for many patients around the world, though to what extent they feel acknowledged and supported can depend on where they live. 9 June 2020
Pharmaceutical
June 9th is International Batten Disease Awareness Day. We take this opportunity to explore the current therapeutic landscape for Batten disease and discuss some of the emerging therapies offering hope for the future. 9 June 2020
Pharmaceutical
The share of Russian drugs in public procurements, which are carried out with the state program for high-cost nosologies program, which involves purchases of the most expensive drugs for the needs of Russian hospitals and other medical institutions – has reached a historic maximum of 42.7% and currently continues to grow, according to recent statements made by some local analysts and Russian media, reports The Pharma Letter’s local correspondent. 9 June 2020
Pharmaceutical
The Russian drugmaker Nanolek has started the development of its own vaccine against COVID-19, and has submitted documents for the production of hydroxychloroquine, a medication which is used in Russia to treat coronavirus, according to the company, reports The Pharma Letter’s local correspondent. 2 June 2020
Pharmaceutical
As the impact of COVID-19 continues to play out in India, pharmaceutical growth has tapered, with the Indian pharmaceutical market registering a sharp decline in sales at minus 11.7% year-on-year (YoY) in April. 1 June 2020
Pharmaceutical
Industry leaders have made further promises about their companies’ sense of responsibility over the development of a vaccine to help humanity to find a way out of COVID-19. 30 May 2020
Pharmaceutical
Sberbank, Russia’s largest state-owned bank, is expanding into the domestic pharmaceutical market, with the establishment of a new company that will focus on the production of drugs, active ingredients, as well as a vaccine against COVID-19, according to recent statements by representatives of the bank and some Russian media, reports The Pharma Letter’s local correspondent. 27 May 2020
Pharmaceutical
Nicholas Jones and Helen Henderson from intellectual property firm, Withers & Rogers, provide an Expert View on how patent bundling could bring unexpected rewards for innovators. 22 May 2020
Biotechnology
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, but serious autoimmune disease, affecting the central nervous system (CNS). This article discusses current pharmaceutical treatments available for NMOSD and explores what is on the horizon for the management of this rare disease. 20 May 2020
Generics
Higher sales of generic drugs and India's Jan Aushadhi initiative, that makes available quality drugs at affordable prices through dedicated stores selling generic medicines, are eating into volumes of branded generics players. As the buying capacity of consumers has reduced in light of the COVID-19 lockdown, there is a growing preference for generics and lower-priced medications, reports The Pharma Letter’s India correspondent. 20 May 2020
Pharmaceutical
Global producers of orphan drugs operating in the Russian market will be able to conduct labeling of their products directly at customs warehouses in Russia in the case of supplies in small batches (up to 10,000 packages), according to recent statements by some senior officials of the Russian Ministry of Health and some local media reports, reports The Pharma Letter’s local correspondent. 19 May 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze